Stocktoria
Silo Pharma, Inc. SILO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-01-05
Silo Pharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $72,102 | $72,102 | $72,102 | $72,102 | — |
| Gross profit | $27,807 | $66,264 | $66,264 | $66,264 | $66,260 |
| R&D expense | $2.2M | $2.4M | $845,092 | $1.3M | $693,910 |
| SG&A expense | — | — | $390,071 | $227,259 | $162,953 |
| Operating income | -$4.3M | -$4.7M | -$3.9M | -$3.6M | -$2.7M |
| Interest expense | — | — | $4,869 | $2,199 | $3,036 |
| Income tax | — | — | — | — | $24,876 |
| Net income | -$4.2M | -$4.4M | -$3.7M | -$3.9M | $3.9M |
| EPS (diluted) | $-0.50 | $-1.19 | $-1.20 | — | $0.04 |
| Operating cash flow | -$4.7M | -$3.8M | -$3.2M | -$3.5M | -$2.3M |
| Cash & equivalents | $4.7M | $3.9M | $3.5M | $11.4M | $9.8M |
| Total assets | $7.6M | $7.4M | $7.7M | $11.6M | $10.5M |
| Total liabilities | $1.3M | $2.4M | $1.6M | $1.3M | $1.4M |
| Shareholders' equity | $6.3M | $5.0M | $6.2M | $10.3M | $9.1M |
Source: SEC EDGAR filings · CIK 0001514183 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.